Grantham, Mayo, Van Otterloo & Co (GMO)’s Charles River Laboratories CRL Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,800	Closed	-$697K	–	719
2019 Q1	$697K	Buy	4,800 +300	+7%	+$39.4K	0.01%	533
2018 Q4	$509K	Buy	4,500 +1,700	+61%	+$213K	﹤0.01%	436
2018 Q3	$377K	Buy	+2,800	New	+$346K	﹤0.01%	464
2018 Q1	–	Sell	-3,500	Closed	-$383K	–	580
2017 Q4	$383K	Buy	3,500 +300	+9%	+$32.6K	﹤0.01%	481
2017 Q3	$346K	Hold	3,200	–	–	﹤0.01%	450
2017 Q2	$324K	Buy	3,200 +700	+28%	+$64.4K	﹤0.01%	454
2017 Q1	$225K	Buy	+2,500	New	+$212K	﹤0.01%	517

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s CRL Position: Q2 2019 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Charles River Laboratories (CRL) in Q2 2019, closing a stake of 4,800 shares — an estimated $697K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in CRL in Q1 2017 and held it in 7 quarters. The position peaked at $697K in Q1 2019. 405 funds tracked by Wall St. Rank hold CRL as of Q2 2019.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Charles River Laboratories position as of Q2 2019 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 4,800 Charles River Laboratories shares in Q2 2019, an estimated $697K.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Charles River Laboratories in Q1 2017 and held it in 7 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Charles River Laboratories position peaked at $697K in Q1 2019.
405 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2019.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2019, filed 13 Aug 2019.